Related Experiment Video
Updated: Apr 14, 2026
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Aaron N Hata1, Jeffrey A Engelman2, Anthony C Faber3
1Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Unlabelled:
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2 family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic apoptotic response. Recent advances in our understanding of apoptotic signaling pathways have enabled methods to identify cancers that are "primed" to undergo apoptosis, and have revealed potential biomarkers that may predict which cancers will undergo apoptosis in response to specific therapies. Complementary efforts have focused on developing novel drugs that directly target antiapoptotic BCL2 family proteins. In this review, we summarize the current knowledge of the role of BCL2 family members in cancer development and response to therapy, focusing on targeted therapeutics, recent progress in the development of apoptotic biomarkers, and therapeutic strategies designed to overcome deficiencies in apoptosis.
Significance:
Apoptosis, long known to be important for response to conventional cytotoxic chemotherapy, has more recently been shown to be essential for the efficacy of targeted therapies. Approaches that increase the likelihood of a cancer to undergo apoptosis following therapy may help improve targeted treatment strategies. Cancer Discov; 5(5); 475-87. ©2015 AACR.
Insights
Cancer cells evade apoptosis, a programmed cell death process crucial for preventing cancer. Targeting BCL2 proteins and identifying biomarkers can enhance apoptosis, improving cancer therapy efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer cells' ability to suppress apoptosis is fundamental to carcinogenesis.
- BCL2 family proteins regulate the intrinsic apoptotic pathway.
- Understanding apoptotic signaling is key to identifying cancers primed for apoptosis.
Purpose of the Study:
- To review the role of BCL2 family members in cancer development and treatment.
- To discuss targeted therapeutics and apoptotic biomarkers.
- To explore strategies for overcoming apoptosis deficiencies in cancer.
Main Methods:
- Review of current knowledge on BCL2 family proteins in cancer.
- Analysis of targeted therapeutics and apoptotic biomarkers.
- Examination of therapeutic strategies to enhance apoptosis.
Main Results:
- Apoptosis is critical for both conventional chemotherapy and targeted therapy efficacy.
- Biomarkers can predict cancer response to apoptosis-inducing therapies.
- Novel drugs targeting antiapoptotic BCL2 proteins are under development.
Conclusions:
- Enhancing cancer apoptosis is essential for improving targeted treatment strategies.
- Apoptosis plays a vital role in the response to various cancer therapies.
- Further research into apoptotic pathways and targeted therapies holds promise for cancer treatment.
More Related Videos
08:51Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:17The Extrinsic Apoptotic Pathway
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Apoptosis